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Abstract 
 
Previously we have shown that conjugation of a palmitic chain via a thioester bond to a cysteine 
residue in weakly- or non-encephalitogenic or neuritogenic peptides markedly enhances their 
ability to induce autoimmune disease in an MHC class II restricted manner. From those studies, 
however, it was not clear whether thiopalmitoylation of the peptides was merely enhancing their 
disease-inducing potential, or whether the lipid was itself playing a pathogenic role. To 
investigate this further, we have now tested the effects of thiopalmitoylation on MHC class II-
restricted altered peptide ligands (APLs), which are normally protective in experimental 
autoimmune encephalomyelitis (EAE), the animal model of multiple sclerosis. We hypothesized 
that if thiopalmitoylation of a peptide merely enhances its innate potential, then 
thiopalmitoylated APLs (S-palmAPLs) should show enhanced protective effects. Alternatively, 
if thiopalmitoylation itself can make a peptide pathogenic, then S-palmAPLs should have 
decreased therapeutic potential. We synthesized APLs and corresponding S-palmAPLs, and 
showed that the S-palmAPLs were much more effective than the non-conjugated APL at 
inhibiting the development of EAE.  This was due to several features of the S-palmAPL: S-
palmAPL-primed cells show an enhanced ability to proliferate and produce the anti-
inflammatory cytokine, IL-10, in vitro. Furthermore, the bioavailability of S-palmAPL was 
greatly enhanced, compared to the non-palmitoylated APL, and S-palm APL was taken up more 
rapidly into DCs and channelled into the MHC class II processing pathway. These results show 
that thiopalmitoylation of MHC class II restricted peptides is a simple way to enhance their 
effects in vivo, and could have wide therapeutic application. 
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Introduction 
 
The role that lipid post-translational modifications to proteins play in the immune response to 
those proteins is still poorly understood. We have been interested in the role that one such 
modification, thiopalmitoylation (attachment of palmitic acid via a thioester bond to cysteine 
residues of a protein), might play in immune responses directed against myelin proteolipid 
protein (PLP), a major component of CNS myelin and a putative autoantigen in the 
demyelinating disease, multiple sclerosis (MS). PLP is normally thiopalmitoylated at up to 6 
sites, at a ratio of approximately 3 moles of lipid per mole of protein; however, it is known that 
the degree of thiopalmitoylation of PLP increases markedly during the process of demyelination 
(1), and thus, during myelin breakdown in MS, there is the potential for thiopalmitoylated PLP 
peptides to be released. Previously, we have shown that thiopalmitoylation of specific PLP 
peptides markedly enhances their encephalitogenicity in an experimental autoimmune 
encephalomyelitis (EAE) model of multiple sclerosis (MS) (2). Similarly, thiopalmitoylation of 
peptides from P0, a major protein of peripheral nervous system myelin, enhances their 
neuritogenic potential in experimental autoimmune neuritis (EAN) (3). The enhanced 
pathogenicity of the thiopalmitoylated peptides appears to be due to their increased uptake 
(compared to non-palmitoylated peptide) into the MHC class II presentation pathway (4, 5). One 
question arising from the above studies is whether the thiopalmitoylation is merely enhancing the 
innate potential of these peptides to be pathogenic, or whether thiopalmitoylation of peptides that 
have little or no disease-inducing potential can actually make them pathogenic. In order to 
address this question, we decided to test the effects of thiopalmitoylation on MHC class II-
restricted altered peptide ligands (APLs) that are normally protective in EAE. We hypothesized 
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that if thiopalmitoylation of a peptide merely enhances its innate potential, then 
thiopalmitoylated APLs (S-palmAPLs) should show enhanced therapeutic efficacy. Conversely, 
if thiopalmitoylation itself can make a peptide pathogenic, then S-palmAPLs should have 
decreased therapeutic potential and/or should become pathogenic. 
 
APLs are analogs of immunogenic peptides that have been modified at one or more key TCR 
contact positions in order to inhibit or modulate the response of T cells that recognise the cognate 
ligand from which the APLs are derived (6, 7). Depending on their particular sequence, APLs 
can i) induce responses in T cells similar to those induced by the cognate ligand, ii) induce some, 
but not all, of the signals and effector functions downstream of the TCR that are generated by the 
cognate ligand, leading to altered patterns of cytokine production or to anergy, or iii) antagonise 
T cell activation by generating a dominant negative signal (6, 8-13). APLs with antagonistic and 
immunomodulatory properties have the potential to therapeutically suppress pathogenic T cell-
mediated autoimmune responses.  
 
In experimental animals, APLs have been found to effectively and reliably dampen autoimmune 
responses, particularly when used at high concentrations (8, 9, 14). Several well-defined APLs 
have been derived from the immunodominant epitopes of PLP for SJL mice, PLP139-151 and 
PLP178-191 (15, 16). For PLP139-151, two APLs have been studied in detail, namely Q144, which 
has a substitution of glutamine (Q) for tryptophan at position 144 (9), and the double substituted 
APL, L144R147 (leucine at position 144 and arginine at position 147 (8, 9). The APL related to 
PLP178-191 is known as A188 and has an alanine (A) at residue 188 instead of phenylalanine 
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(14). Both Q144 and A188 appear to exert their in vivo effects predominantly through increasing 
levels of the cytokines IL-4, IL-10 and IFN- (9, 14).  
 
In the current study, we compared the effects of non-palmitoylated APLs (A188 and Q144) and 
the corresponding S-palmAPLs to determine whether or not S-palmAPL are themselves 
encephalitogenic and lose the therapeutic efficacy of the non-palmitoylated APLs, or whether the 
protective effects of the APL are enhanced by thiopalmitoylation. We show that S-palmAPLs 
show greatly enhanced protective effects, and that this appears to occur because of the effects of 
thiopalmitoylation on stability of the peptide in serum, increased uptake of the APL into the 
MHC class II presentation pathway, and induction of greatly enhanced levels of IL-10 following 
S-palmAPL administration. The enhanced levels of IL-10 also appear to induce bystander 
effects, enabling S-palmAPL to inhibit the encephalitogenicity of unrelated peptides in vivo. 
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Materials and Methods 
 
Peptide Synthesis 
Peptides (Table 1) were manually synthesized by solid phase-synthesis using the Fmoc/tBu 
strategy. Thiopalmitoylation of residue Cys at position 183 was performed on the resin-bound 
peptide after selective deprotection of the Cys(Mmt) side chain (17). The biotin-labelled 
thiopalmitoylated peptides were synthesized as we have previously described (4). After cleavage 
from the resin, the crude peptides were lyophilized and purified by reverse phase HPLC (RP-
HPLC). The purity of the peptides was assessed by analytical HPLC and their identities were 
confirmed by MALDI-TOF mass spectrometry. 
 
For injections into mice and for in vitro tissue culture, stock solutions of 5 mg/mL peptides 
dissolved in 0.2M acetic acid were further diluted in phosphate-buffered saline (PBS) or tissue 
culture medium immediately prior to use. For the uptake experiments, stock solutions of pure 
biotinylated peptides were made up at a concentration of 5 mg/mL in H2O (A188-Biot), or in 
30% DMSO (S-palmA188-Biot).  
 
EAE induction and clinical assessment 
SJL/J mice were purchased from the Animal Resources Centre (Murdoch, Western Australia), 
and were immunized at 6-8 weeks of age. Mice were maintained and used in accordance with the 
University of Queensland ethical guidelines for use of experimental animals, and the 
experimental protocol was approved by the Animal Ethics Committee of the University of 
Queensland. 
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For induction of EAE, 32-65 µmoles of peptide and 400 μg of M. tuberculosis H37Ra (Difco, 
Detroit, MI, USA) in an emulsion consisting of equal volumes of PBS and CFA was injected 
subcutaneously on the back of the mouse. Each mouse also received 300 ng of Bordetella 
pertussis toxin (Sapphire Biosciences, Redfern, NSW, Australia) i.v on day 0 and day 3. Clinical 
assessment (weighing & observation) was conducted daily from day 7 post-injection. Mice were 
scored according to the following criteria: 0, no disease; 1, decreased tail tone or slightly clumsy 
gait; 2, tail atony and/or moderately clumsy gait and/or poor righting ability; 3, hind limb 
weakness; 4, hind limb paralysis; 5, moribund state. For co-immunisation experiments, APLs or 
S-palmAPLs, at different molar ratios, were included in the emulsion with the adjuvant. 
 
T cell proliferation assays 
Mice were immunised s.c. with 32 µmoles of PLP178-191, A188, or S-palmA188 peptide in an 
emulsion consisting of equal volumes of PBS and CFA (Difco). Ten days after immunisation, 
mice were euthanized, and axillary and inguinal lymph nodes were removed and teased apart. 
Lymph node cells (LNC) pooled from at least 2 mice were washed twice with sterile PBS and 
stained with 2 µM Carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Life 
Technologies, Melbourne, Australia) for 30 min at 37 °C. Cells were cultured at 4x106/mL in 
phenol red-free RPMI 1640 (Life Technologies) containing 10% Serum Supreme (Lonza 
Australia, Melbourne, Australia), 2mM HEPES (Lonza), 50μM 2-ME (Sigma-Aldrich, Sydney, 
Australia), and 2mM l-glutamine (Lonza), in the presence or absence of antigen (25 µg/mL) for 5 
days. Wells with no antigen and ConA (2 μg/mL) were used as negative and positive controls, 
respectively.  
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After 5 days, cells were harvested and washed with PBS containing 1% FCS and 0.01% sodium 
azide (Sigma) (wash buffer), before staining with Per-CP-labelled anti-CD4 or anti-CD8 
antibodies (BD Biosciences, Sydney, Australia) for 1h at 4°C in the dark. Per-CP-labelled 
isotype-matched primary antibodies (BD Biosciences) were used as controls. Stained cells were 
analysed on a FACSCalibur flow cytometer using CellQuest Software (BD Biosciences). All 
staining profiles were based on lymphocyte-gated cells, as determined by forward and side 
scatter properties. The results are expressed as a percentage of CD4+ or CD8+ cells in the sample 
that are dividing (reactive) in response to the antigen, and a cell division index (CDI) was 
calculated by dividing the percentage of dividing cells in the antigen-stimulated group by the 
percentage of dividing cells in the control group (no antigen). Assays were done in triplicate. 
 
Cytokine ELISA 
Culture supernatants were collected after 72 h from LNC cultured with antigen as for 
proliferation assays, and stored frozen at -80°C until use. Ready-Set-Go sandwich ELISA kits 
(eBiosciences, San Diego, CA) specific for IL-10, IL-17, and IFN-γ were used to determine the 
concentration of cytokines in the supernatants, as per the manufacturers’ instructions. Each 
supernatant was tested in triplicate, and the concentrations of cytokines were determined from 
comparison against standard curves prepared from serial dilutions of recombinant cytokines 
tested on the same plate as the test samples. Results from duplicate assays were calculated and 
graphed as a fold change in concentration of stimulated cells compared to 
unstimulated/background (no antigen) levels.  
 
Cytokine Bead Array (CBA) assay for measuring levels of IL-10 and IFN-  
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Levels of the cytokines IL-10 and IFN-γ in culture supernatants from control or antigen-
stimulated LNC of mice coimmunized with PLP139-151 and A188 or S-palmA188 were 
quantitated using CBA Mouse IL-10 (bead C4) and IFN- (bead A4) sets (BD Biosciences, 
Franklin Lakes, NJ, USA), as per the manufacturer’s instructions. Briefly, undiluted culture 
supernatant was incubated with cytokine capture antibody-bead complexes and PE-conjugated 
antibody (specific for beads) for 2hrs. Data was acquired using a BD FACScalibur flow 
cytometer and analysed using FCAP software (BD Biosciences). The concentrations of each 
cytokine (pg/ml) were determined from a standard curve generated using 10 serial dilutions of 
cytokine standards. 
 
Stability of APL and S-palmAPL in serum 
Peptide (500 g) was dissolved in 900 L of 0.05 M phosphate buffer (pH 7.2) containing 1% 
acetonitrile. Fetal calf serum (10% serum, v/v) was added (100 L). The reaction mixture was 
incubated at 37 °C. At different incubation times, a 100 L aliquot was collected, and protease 
activities were blocked by adding 2 vol of acetonitrile (200 L). After centrifugation at 3000 rpm 
for 5 min, the supernatant was analyzed by RP-HPLC. In these conditions, no peptide 
precipitated. A control sample was run in the absence of peptide. 
 
Uptake and presentation of APL and S-palmAPL by DC 
Dendritic cells (DC) were isolated from spleens of SJL/J mice (Janvier, Le Genest-Saint-Isle, 
France) using positive selection with CD11c+ MicroBeads (N418) (Miltenyi Biotec, Paris, 
France) as per the manufacturer’s instructions. DC were resuspended in RPMI medium 
containing 5% FCS and 5ng/mL GM-CSF and allowed to adhere to glass coverslips for 2hrs at 
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37 °C. Non-adhered cells were washed off and DC were then incubated with 100 M of 
biotinylated peptide for between 5min to 1 h at 37°C. After incubation, cells were fixed with 4% 
formaldehyde in PBS for 15 min at room temperature and permeabilized with 0.2% triton X100 
in PBS for 5 min at room temperature.  
 
For assessment of the amount of peptide taken up by DC, DC were next incubated with 
streptavidin-Alexa 488 (1/400 dilution in PBS) (Invitrogen, Cergy Pontoise, France) to detect the 
biotinylated peptide. In experiments to assess MHC class II colocalization, cells were incubated 
after fixation and permeabilization with Anti-Mouse I-Ap (anti-MHC class II; cross reacts with I-
As) (FITC labelled) (1/100 dilution in PBS) (BD Biosciences, Le Pont de Claix, France) 
overnight at 4°C and then with Streptavidin-Cy3 (1/400 dilution in PBS) (Invitrogen) at room 
temperature for 45 min. After staining, cells were washed in PBS, and coverslips were mounted 
using Aquapolymount medium. Immunofluorescence staining was monitored with a laser 
scanning microscope (Leica SP5 II) equipped with a Leica HCX PL APO 63x oil DIC 
immersion lens (numerical aperture 1.4-0.6).  
 
Uptake of APL and S-palmAPL was also compared using flow cytometry. DC in suspension 
were incubated with 10μM of the different biotinylated peptides for 10 min at 37 °C. At the end 
of the incubation, cells were washed and incubated with anti-CD11c (APC labelled) and anti-I-
Ap (FITC labelled) (1/300 dilution) (BD Biosciences) to detect dendritic cells. After washing, the 
cells were fixed and permeabilized with BD Cytofix/Cytoperm and incubated with PE-
streptavidin to detect the biotinylated peptides. The cells were analyzed by flow cytometry using 
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a FACSCalibur system (Becton Dickinson). Samples were gated on the CD11c+/I-Ap+ 
population, and the mean fluorescence intensity of staining with PE-streptavidin was determined.  
 
Statistics 
Most statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego, 
California, USA). Normality tests were initially performed to determine whether or not the data 
was normally distributed. Differences between more than two groups were tested using ANOVA 
(for parametric data) or the Kruskal-Wallis test (for nonparametric data). If analysis of the group 
as a whole showed a significant difference (p<0.05), then appropriate post-tests (Dunnett’s test 
with ANOVA or Dunn’s Multiple Comparisons test with Kruskal-Wallis) were used to compare 
pairs of groups. For analysis of the course of EAE, multiple time point 2-way ANOVA was used. 
For comparison of disease incidence in mice, χ2 analysis with Yates’ correction was used. The 
log-rank (Mantel Cox) test was used to compare survival curves (showing percentage of mice 
free of EAE). 
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Results 
 
Effects of thiopalmitoylation of APLs on their protective effects in vivo 
The APL A188 is derived from the encephalitogenic peptide PLP178-191, by substituting an 
alanine (A) for phenylalanine at position 188. A188 is not encephalitogenic in vivo and is able to 
protect against the induction of PLP178-191-induced EAE in SJL/J mice when it is used at a 
higher molar ratio than the inducing peptide (14). A188 and S-palmA188 were synthesized by 
solid phase-synthesis (Table 1); the palmitic chain was linked via a thioester bond to Cys183 in 
the S-palmA188 peptide. We then compared the effects of A188 and S-palmA188. Initial studies 
showed that neither A188 nor S-palmA188 were encephalitogenic when the peptides (emulsified 
in CFA) were injected into SJL/J mice (Table 2). Next, mice were co-immunized with mixtures 
of encephalitogenic PLP178-191, together with either A188 or S-palmA188 at various molar 
ratios, and followed for development of EAE. The protective effect of A188 was significantly 
enhanced by thiopalmitoylation, as evidence by decreased incidence of disease, increased mean 
day of onset, and decreased mean severity of EAE (Table 2 and Figure 1). When S-palmA188 
was injected at a ratio of 1:1 with PLP178-191, animals were completely protected from disease; 
in contrast, EAE in mice treated with non-palmitoylated A188 at a 1:1 ratio with PLP178-191 did 
not differ significantly from mice injected with PLP178-191 alone (Table 2). In addition, a 
substantially smaller quantity of S-palmAPL than A188 was required to induce the same clinical 
effect, with 1:0.1 PLP178-191:S-palmA188 treatment giving the same outcome as 1:5 PLP178-
191:A188 (Figure 1). 
 
In order to ensure that the protective effects observed were not restricted to a single APL, we 
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also tested the APL Q144, derived from the encephalitogenic peptide PLP139-151 (Table 1). 
Previous work has shown that Q144 induces a highly Th2 polarized response and is effective at 
inhibiting EAE induced by PLP139-151 at a 1:6 ratio of PLP139-151:Q144 (9). As shown in Table 
2, the protective effect of Q144 was also enhanced when the peptide was palmitoylated on 
Cys150. 
 
Effects of A188 and S-palmA188 on T-cell proliferative responses 
We have previously shown that the APL A188 protects against EAE primarily via induction of 
A188-specific CD4+ Th0/Th2 cells (14). To determine if a stronger A188-specific CD4+ T cell 
response was induced in mice immunized with the thiopalmitoylated peptide, we next compared 
the proliferation of CD4+ and CD8+ T cells from mice immunized with A188, S-palmA188, or 
PLP178-191, in response to PLP178-191 or A188. We have used A188 to stimulate T cells 
generated in mice immunized with either A188 or S-palmA188, as we have shown in a previous 
study that the lipid tail is cut off the peptide within the endosomes or lysosomes of the antigen-
presenting cells, due to the presence of thioesterases in these organelles (5); thus, the T cells 
would recognize only the A188 portion of the molecule, irrespective of whether the antigen-
presenting cells take up non-palmitoylated peptide or thiopalmitoylated peptide. 
 
LNC from mice immunized 10 days previously with A188, S-palmA188, or PLP178-191 were 
stained with CFSE and stimulated with antigen in vitro for 5 days. LNC were subsequently 
stained with anti-CD4 or anti-CD8 antibodies and analysed to assess cell proliferation. Very few 
proliferating CD8+ cells were detected (data not shown). CD4+ T cells proliferated in an antigen-
specific manner (Table 3). Most notably, the percentage of proliferating A188-specific T cells 
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was twice as high in LNC from mice immunized with S-palmA188 (10.7% ± 2.6%) than in LNC 
from mice immunized with A188 (5.2% ± 1.5%), showing that thiopalmitoylation efficiently 
enhances the proliferation of CD4+ T cells. PLP178-191-specific T cells proliferated minimally 
following stimulation with A188, but proliferated strongly in response to PLP178-191. There were 
no significant differences in the ability of the LNC from mice immunized with A188 or S-
palmA188 to proliferate in response to PLP178-191, or to the unrelated PLP139-151 peptide. 
 
 Cytokine production induced by immunization with A188 and S-palmA188 
Previously we have reported that A188-specific T cells have elevated levels of mRNA for the 
cytokines IL-4, IL-5, IL-10 and IFN-, compared to controls, and have speculated that the APL 
prevents EAE by inducing the production of Th0 and Th2 cytokines by A188 specific cells (14). 
Since the time when those experiments were done, Th17 cells have been shown to play an 
important role in the development of EAE (18). To evaluate the effect of thiopalmitoylation of 
A188 on the production of cytokines we measured levels of 3 key cytokines (IFN-, IL-10 and 
IL-17A). Culture supernatants were collected from 72 h in vitro cultures (in the presence of no 
antigen, PLP178-191 or A188) of LNC from mice that had been immunized with PLP178-191, 
A188, or S-palmA188. Significant differences were seen amongst the different groups with 
respect to production of IFN- IL-10, and IL-17A (Figure 2).  
 
Following in vitro stimulation with PLP178-191, LNC from mice immunized with PLP178-191 
showed a greater than 500-fold increase in the amount of IL-17A produced, and smaller fold 
changes in levels of IFN- and IL-10. After in vitro stimulation with A188, these same LNC 
increased production of IL-10, but showed minimal increases in levels of IFN- and IL-17. In 
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contrast, LNC from mice immunized with A188 or S-palmA188 cells showed no increases in the 
amounts of IL-17 when stimulated in vitro with either A188 or PLP178-191. A188-specific and S-
palmA188-specific LNC both increased production of IFN-γ in response to A188 stimulation, 
but not when stimulated with PLP178-191. The most significant finding from this experiment was 
the greatly enhanced ability of S-palmA188-specific LNC to produce the anti-inflammatory 
cytokine IL-10 following stimulation with A188 (P<0.001 compared to other groups). 
 
S-palmA188, but not A188, can induce bystander suppression of PLP139-151-induced EAE. 
Because S-palmA188 was able to induce production of significantly higher levels of the anti-
inflammatory cytokine IL-10 than could A188, we next tested whether some of the effects of the 
S-palmA188 might be due to bystander suppression of pro-inflammatory responses in a non 
antigen-specific manner. To test this, mice were immunized with 32 μmoles of PLP139-151 alone, 
32 μmoles PLP139-151 + equimolar amount of A188, or 32 μmoles PLP139-151 + equimolar 
amount of S-palmA188. Mice were then followed for 35 days. All mice immunized with PLP139-
151 developed EAE, although since the amount of PLP139-151 used to induce disease was less 
than half of the amount used for disease induction in the mice in Table II, the average day of 
onset of EAE was sightly later than that shown in Table II (Figure 3A) and the mean severity 
was lower (2.8 ± 0.4). Three of four mice coimmunized with PLP139-151 and A188 also 
developed EAE with the same kinetics of disease (Figure 3A). In contrast, only two of eight mice 
coimmunized with PLP139-151 and S-palmA188 developed EAE (Figure 3A). In the 3 A188-
coimmunized and 2 S-palmA188-coimmunized mice that did develop EAE, disease severity was 
not significantly less than that seen in the mice immunized with PLP139-151 alone. These results 
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strongly suggest that a bystander response induced by S-palmA188 was sufficient to overcome 
the encephalitogenicity of PLP139-151. 
 
To investigate whether this non antigen-specific protection might be due to the production of IL-
10 and/or IFN, LNC were removed from the above mice on day 35 after immunization. At the 
time when LNC were collected, all mice were in the recovery or remission phase of disease. 
Cultures were set up from each individual mouse’s LNC to assess the production of IL-10 and 
IFN- upon stimulation of the LNC with either no antigen, PLP139-151 or A188. After 3 days in 
vitro stimulation, culture supernatants were harvested and the levels of IL-10 and IFN- in the 
supernatants were assessed using CBA assays. All mice were found to make a low level of IL-10 
upon stimulation with PLP139-151 (Figure 3B). However, only LNC from mice coimmunized 
with either A188 or S-palmA188 made significantly increased amounts of IL-10 upon 
stimulation with A188 (Figure 3B). A188-coimmunized mice had a 12-fold increase in IL-10 
levels, compared to the no antigen group. In S-palmA188-coimmunized mice, there was a 19.4-
fold increase in IL-10 levels. Significant fold changes in levels of IFN- were also seen in the 
mice co-immunized with either A188 or S-palmA188 (3.6 fold increase in each, compared to no 
antigen group). These results support the proposition that the production of significant amounts 
of IL-10 by cells responding to S-palmA188 can act non-specifically to decrease the 
encephalitogenic response normally induced by PLP139-151. Since A188 co-immunized mice 
also produced reasonable amounts of IL-10, it may be that there is a threshold amount of IL-10 
required to induce protection from EAE, which was not quite reached in the A188-treated 
animals.  
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Stability of A188 and S-palmA188 in the presence of serum 
Another potential reason for the enhanced effectiveness of S-palmA188 in vivo could relate to its 
bioavailability. We therefore next investigated the stability of A188 and S-palmA188 in the 
presence of serum. For this purpose, both peptides were incubated in phosphate buffer in the 
presence of 10% FCS, and the progress of the digestion was followed by HPLC. As shown in 
Figure 4, the S-palm peptide exhibited greater stability than the non-palmitoylated peptide, since 
most of the A188 was digested after 3 h, while 85% of S-palmA188 remained undigested at that 
time point. The half-life of S-palmA188 was significantly longer (>850 min) than that of A188 
(50 min), which would enhance the bioavailability of S-palmA188. 
 
Uptake of A188 and S-palmA188 by DCs  
DCs are the professional APC of the immune system. Previously, we have found that 
thiopalmitoylated encephalitogenic peptides are not only taken up more efficiently by another 
type of APC (macrophages) than are the same non-palmitoylated peptides, but are also 
channelled into the MHC class II presentation pathway, and we have proposed that this underlies 
their improved immunogenicity and the enhancement of CD4+ T cell responses (4, 5). In this 
study, we sought to confirm whether S-palmAPL was taken up more efficiently than non-
palmitoylated APL by DCs.  
 
DCs were purified from spleens of SJL/J mice and incubated for 10 min in the presence of 
biotinylated S-palmA188 or non-palmitoylated A188 (Table 1). PE-conjugated streptavidin was 
used to detect the peptide taken up by these cells by flow cytometric analysis. 
Thiopalmitoylation enhanced the uptake of APL by DCs, as indicated by higher levels of PE 
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staining (Figure 5A). This was further confirmed using confocal microscopy on purified splenic 
DCs incubated with the APL and S-palmAPL for different times (Figure 5B-F). S-palmA188 
could be easily detected at the cellular membrane after 5 min (Figure 5B), and after just 15 min 
the translocated peptide showed a punctate fluorescence staining pattern, indicative of 
localization in discrete vesicular compartments and suggestive of an endocytic pathway of 
internalization (Figure 5 C-E). In contrast, even after 60 min, hardly any non-palmA188 peptide 
had been taken up into DCs (Figure 5F). These results confirm that the palmitic chain markedly 
enhances the efficiency of peptide translocation into DCs.  
 
We have previously demonstrated with encephalitogenic thiopalmitoylated peptides that the 
thioester bond between the lipid and peptide can be broken down in endosomes and lysosomes 
(part of the MHC class II presentation pathway and which contain thioesterases), thereby 
effectively “stranding” the peptide in these organelles, and making it much more likely that they 
will be presented by MHC class II molecules (5). In order to assess if this same mechanism was 
likely to be occurring with the S-palmA188 peptide, we investigated whether there was co-
localization of biotinylated peptide and MHC class II  in DCs that has been incubated with the 
biotinylated peptide for 60 min. Most of the biotinylated peptide (detected using Streptavidin-
Cy3) co-localized with MHC class II (Figure 5G). These results confirm that the thioester bond 
between lipid and peptide helps to channel the peptide into the MHC class II presentation 
pathway, due to the presence of thioesterases in these organelles, thereby inducing a CD4+ T cell 
response, as we have previously found with encepalitogenic peptides in macrophages (5). 
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Discussion 
In the current study, we have shown that thiopalmitoylation of APLs can enhance their protective 
properties. Using a co-immunisation protocol, we showed that thiopalmitoylation greatly 
enhanced the prophylactic abilities of the A188 APL (Figure 1 and Table 2), with a 50-fold 
lesser quantity of S-palmA188 needed to induce the same protective effects as non-palmitoylated 
A188. The complementary data obtained from S-palmQ144 show that the enhancement of the 
protective effects afforded by thiopalmitoylation is not exclusive to one APL, but can be 
generalized to other APLs. These results support the idea that thiopalmitoylation of a peptide 
enhances its innate properties; thus, thiopalmitoylation of a peptide that has the potential to be 
pathogenic can enhance pathogenicity (as we have previously shown in EAE (2, 5), and EAN 
(3)), whereas thiopalmitoylation of a peptide that has the potential to protect against disease can 
enhance the efficacy of the therapeutic effect. This could have potential applicability in vaccine 
development, providing a simple means to increase MHC class II restricted T cell responses.  
 
There appear to be several mechanisms that are operative in the enhancement of immunogenicity 
of the A188 APL by thiopalmitoylation. Firstly, thiopalmitoylation greatly enhanced the stability 
and longevity of A188 peptide in serum, with S-palmA188 having a half-life more than 15 times 
that of the non-palmitoylated APL in the presence of serum (~875 min vs 42 min, respectively). 
This could be due to formation of micelle-like aggregations or particles, as has previously been 
reported for N-palmitoylated peptides (19, 20). The characteristic of enhanced stability in serum 
is yet to be confirmed for other S-palm peptides; however, the increase in bioavailability is 
almost certainly one element important for the enhanced immunological activity and in vivo 
effects of S-palmA188.  
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Secondly, uptake of S-palmA188 compared to A188 into the class II MHC presentation pathway 
of DC was greatly enhanced. Transient thioacylation, particularly by attachment of myristic acid 
(C14) or palmitic acid (C16), is a common mechanism that cells use to move molecules through 
membranes; this can occur via non-phagocytic mechanisms, endocytosis or patocytsis [reviewed 
in (21)]. Our previous work suggests that thiopalmitoylation of PLP peptides allows uptake via 
non-phagocytic mechanisms (5). Furthermore, using S-palm peptides in which the palmitic acid 
is replaced by a fluorescent lipid analogue, we have previously shown that the lipid moiety is 
cleaved from the peptide within endosomes, thereby stranding the peptide moiety in the 
endosome (5); this would account for the preference for the class II MHC pathway, as the 
endosomes are part of this pathway.  
 
Lastly, S-palmA188-primed cells, compared to those primed by A188, showed an enhanced 
ability to proliferate (Table 3) and to produce the anti-inflammatory cytokine IL-10 (Figure 2) in 
the presence of APL stimulation; this can explain the increased efficacy of S-palmA188 in vivo 
compared to non-conjugated A188. Interestingly, both A188- and S-palmA188-primed cells 
produced copious amounts of IFN-γ, a cytokine often regarded as pro-inflammatory; however, it 
is known that IFN- can inhibit Th17 responses (22, 23) and, furthermore, several studies have 
reported more severe and chronic disease in anti-IFN-γ antibody treated (24) and IFN-γ gene 
knock-out (25) EAE models. Taken together, these findings support the idea that IFN-γ can 
cause down-regulation of pathogenic Th17 mediated disease (26). It is also of interest to note 
that development of mucosal tolerance to another myelin antigen, MBP, has recently been 
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reported to be mediated by a Th0 cell population producing both IFN- and IL-10 (27), similar to 
the phenotype of the S-palmA188-specific cells reported here.  
 
Because of the induction of copious amounts of IL-10 in mice immunized with S-palmA188, we 
also tested the potential of S-palmA188 to protect against induction of EAE with an unrelated 
antigen. As shown in Figure 3, coimmunization with S-palmA188, but not A188, effectively 
protected against disease induced by PLP139-151. This protection correlated with enhanced 
production of IL-10 in the mice co-immunized with PLP139-151 and S-palmA188. There was also 
an elevated level of IL-10 produced in mice co-immunized with PLP139-151 and A188, although 
not to extent of that induced by S-palmA188. These results suggest that S-palmAPLs could 
potentially have both specific and non-specific bystander therapeutic effects: in a therapeutic 
setting, this could be a distinct advantage.  
 
A small number of human APL trials have been undertaken in patients with autoimmune disease 
(28-32); they have not been very successful thus far, although this has been due largely to trial 
design issues such as poor selection of APLs (using APLs that were capable of acting as full 
agonists for some patient T cell clones (33, 34)) and of patients (not screening patients to ensure 
that they carried the specific HLA molecules for which the APLs were designed). However, part 
of the lack of success of the human APL trials also stems from the poor in vivo stability and low 
immunogenicity of peptides, and the severe injection-site reactions that developed when very 
large amounts of peptide were administered to try to overcome these issues. The findings in the 
current study suggest that S-palmAPL may have significant advantages over APLs in future 
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human trials, given their markedly increased stability and immunogenicity, provided APL- and 
patient-selection issues are adequately addressed.  
 
Thiopalmitoylation of other types of peptide vaccines may also help to enhance CD4+ T cell 
mediated prophylactic or therapeutic effects. For example, current studies are trying to find a 
way to enhance CD4+ T cell responses to cancer vaccines, so as to promote more robust priming 
and long-term protective CD8+ T cell responses (35). Thiopalmitoylation of peptides may be one 
way to achieve this. The protective effects of the S-palmAPLs do not appear to be dependent on 
the position in the peptide chain of the cysteine residue to which the palmitic chain is linked via a 
thioester bond, as this was the second residue for PLP139-151 and the sixth residue for PLP178-
191. If a peptide does not contain a cysteine in its sequence, it may be possible to replace an 
existing serine with a cysteine without affecting the biological activity (3), or to add a cysteine at 
the N- or C- terminus of the peptide. 
 
Taken together, our results suggest that the strategy of thiopalmitoylation of a peptide has great 
potential to enhance CD4+ T cell responses to that peptide. The lipid group does not change the 
type of response that is induced; it merely enhances the type of response that the peptide has the 
capacity to induce. We provide evidence that S-palmAPL can be highly efficient at a much lower 
dose than the non-palm APL. This strategy could effectively and safely enhance APL therapy for 
many autoimmune and inflammatory diseases, including MS, diabetes type 1, rheumatoid 
arthritis and myasthenia gravis. Thiopalmitoylated peptides also have the potential to enhance 
immunogenicity of peptide vaccines that aim to induce a CD4+ T cell response. 
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Figure Legends 
 
 
Figure 1. A) Clinical course of EAE in mice immunized with PLP178-191, PLP178-191 + A188 
(at 1:5 ratio), or PLP178-191 + S-palmA188 (at 1:1 and 1:0.1 ratios). At 1:1 ratio, the S-
palmA188 completely prevented onset of EAE (P<0.0001 compared to PLP178-191 at days11-17 
and P<0.01 at day 18). S-palmA188 at 1:0.1 ratio was as effective as A188 at 1:5 ratios; both of 
these were significantly less than the PLP178-191 group at days12-18. B) The percentage of mice 
free of EAE. All mice in the PLP178-191 group had developed EAE by day 14 after induction of 
EAE. All mice in the S-palmA188 (1:1) group remained free of disease, which was highly 
significantly different from the PLP178-191 group (P<0.0001). Around 60% of the mice in both 
the A188 (1:5) and S-palmA188 (1:0.1) groups remained free of EAE (P values given next to 
these lines are for the comparison with the PLP178-191 group). 
 
Figure 2. Production of cytokines (IFN-, IL-10, IL-17) by LNC from mice immunized with 
PLP178-191, A188 or S-palmA188 following stimulation with PLP178-191 (black bars) or A188 
(stippled bars), as indicated by fold change compared to unstimulated cells. Background levels of 
cytokines were: IFN- - 37.5 ± 10.5 pg/ml; IL-10 - 54.3 ± 17.6 pg/ml; IL-17 - 5.1 ± 0.9 pg/ml. 
 
Figure 3. S-palmA188 can induce non antigen specific protection in the coimmunization model, 
probably through induction of a Th0-like response. A) Mice were immunized with PLP139-151 
alone or coimmunized with PLP139-151 together with A188 or S-palmA188. The percentage of 
mice free of EAE is shown. All mice immunized with PLP139-151 alone (n=8) developed EAE, 
as did 3 of 4 mice coimmunized with PLP139-151 and A188. In contrast, only 2 of 8 mice 
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coimmunized with PLP139-151 and S-palmA188 developed EAE, which was significantly 
different to the control group (P=0.0002 by the Log-rank (Mantel-Cox) test). B) At day 36 after 
the commencement of the coimmunization experiment, lymph node cells were removed from 
each mouse and activated in vitro with no antigen, PLP139-151 or A188. After 72 hours, 
supernatants from each culture were harvested and subsequently tested for production of IL-10 
and IFN- in CBA assays. The levels of cytokines (mean ± SE for each group of mice) are 
expressed as pg/ml. 
 
Figure 4: Kinetics of digestion of A188 and S-palmA188 in the presence of serum. The dotted 
lines show the half-lives (t1/2) of each peptide. 
 
Figure 5: The uptake of A188 and S-palmA188 peptide by splenic DCs. (A) Peptide uptake after 
10 min indicated by fluorecent intensity measured via flow cytometry. (B-F) Confocal 
microscopy analysis of uptake of biotinylated peptides (stained green): B-E) Uptake of S-
palmA188 after the indicated times or F) uptake of A188 after 60 min. G) Colocalization of 
MHC class II and peptide indicated by merging (yellow) of MHC class II staining (green) and 
peptide staining (red). Scale bar 5 m 
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TABLES 
 
Table 1. Designation and sequences of the synthetic peptides used in this study. 
 
Peptide designation Sequence 
PLP178-191 (native sequence) NTWTTCQSIAFPSK 
A188 NTWTTCQSIAAPSK 
S-palmA188 NTWTTC(Palm)QSIAAPSK 
A188-Biotin NTWTTCQSIAAPSK(Biot)
S-palmA188-Biotin NTWTTC(Palm)QSIAAPSK(Biot) 
PLP139-151 (native sequence) HCLGKWLGHPDKF 
Q144 HCLGKQLGHPDFK 
S-palmQ144 HC(Palm)GKQLGHPDFK 
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Table 2. The effect of A188 and S-palmA188 on induction of EAE with PLP178-191 and of Q144 and S-palmQ144 on induction of EAE 
with PLP139-151 in co-immunization experiments at different ratio  
 
Immunized with: 
(molar ratio) 
Incidence 
Day of onseta 
(mean ± SE) 
Average scoresb 
(mean ± SE) 
Severity score c 
(mean ± SE) 
Disease durationd
(mean ± SE) 
PLP178-191 8/8 11.3 ± 0.5 2.8 ± 0.3 2.8 ± 0.3 6.4 ± 1.1 
A188 alone 0/4 - 0 0 0 
S-palmA188 0/4 - 0 0 0 
PLP178-191 + A188 (1:5) 5/12* 11.5 ± 0.4 1.0 ± 0.4** 2.8 ± 0.4 1.8 ± 0.9** 
PLP178-191 + A188 (1:1) 3/4 11.3 ± 0.7 1.9 ± 0.8 2.5 ± 0.9 3.3 ± 1.5 
PLP178-191 + S-palmA188 (1:1) 0/8* -† 0*** 0† 0*** 
PLP178-191 + S-palmA188 (1:0.2) 3/7 14.7 ± 0.9* 0.5 ± 0.3** 1.2 ± 0.4 0.7 ± 0.4** 
PLP178-191 + S-palmA188 (1:0.1) 3/8 11.7 ± 0.2 0.9 ± 0.4** 2.3 ± 0.2 2.5 ± 1.5* 
PLP139-151 4/4 11.5 ± 0.9 4.3 ± 0.3 4.3 ± 0.3 8.3 ± 0.9 
PLP139-151 + Q144 (1:6) 3/4 11.3 ± 0.6 2.1 ± 0.7* 2.8 ± 0.4* 4.3 ± 1.5 
PLP139-151 + S-palmQ144 (1:6) 0/4* -† 0*** 0† 0*** 
PLP139-151 + S-palmQ144 (1:1) 1/3 21† 0.7 ± 0.7** 2† 1.3 ± 1.3** 
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a Average of the day post immunisation that first clinical signs were recorded in the mice that developed EAE 
b Average of the scores of all mice 
c Average of the scores of mice that developed EAE;  
d Average of the number of consecutive days an EAE score was recorded 
* P < 0.05; ** P < 0.01; and ***P < 0.001 compared to mice immunized with PLP178-191 or PLP139-151 alone 
†Statistical analyses could not be done for these groups due to <3 mice/group with EAE
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Table 3. Assessment of proliferation of antigen-primed CD4+ cells, as determined by 
CFSE and anti-CD4 antibody staining and flow cytometry 
 
Antigen-primed  
LNC 
Stimulating  
Antigen¶ 
% dividing CD4+ cells 
(Mean ± SE) † 
Cell division 
index 
A188 None 1.1 ± 0.2  
 A188 5.2 ± 1.5* 4.6 
 PLP178-191 1.4 ± 0.3 1.2 
 PLP139-151 1.4 ± 0.3 1.2 
S-palmA188 None 0.9 ± 0.2  
 A188 10.7 ± 2.6** 12.2 
 PLP178-191 1.6 ± 0.45 1.8 
 PLP139-151 2.6 ± 1.3 2.9 
PLP178-191 None 1.5 ± 0.5  
 A188 2.5 ± 0.8 1.7 
 PLP178-191 21.4 ± 8.3* 14.3 
 PLP139-151 2.9 ± 1.3 1.9 
 
*P<0.05; **P<0.01 compared to no antigen control of LNC primed with the same antigen 
¶ ConA was also used as a positive control in all assays (data not shown) 
†Results are the mean ± SE of 3 replicate experiments 
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